ArticleAmerican journal of cancer research2026
LAMP5 as a novel prognostic biomarker linked to the tumor immune microenvironment in esophageal squamous cell carcinoma.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentifying reliable prognostic biomarkers and elucidating their cellular origins in the tumor microenvironment (TME) is crucial for improving esophageal squamous cell carcinoma (ESCC) management.
methodsDifferentially expressed genes were identified from GSE53624 and GSE32424 datasets. LASSO-Cox regression generated a prognostic risk signature, and a nomogram was built for overall survival prediction. CIBERSORT assessed immune infiltration. Experimental validation included qPCR, immunohistochemistry, and functional assays in cell lines and clinical specimens (n = 65). Lysosomal-associated membrane protein 5 (LAMP5)-modified ESCC cells were co-cultured with CD8
resultsA four-gene prognostic signature was established; LAMP5 demonstrated the strongest independent prognostic value (area under the curve = 0.773). LAMP5-associated genes were enriched in immune-related pathways. Overexpression of LAMP5 promoted malignant behavior, inhibited ESCC cell apoptosis, and suppressed CD8
conclusionLAMP5 is associated with immune responses in the TME and acts as a promising novel biomarker for ESCC. Its overexpression inhibits CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.